Alembic Pharmaceuticals Secures USFDA Nod for Ophthalmic Emulsion..

Varahi media.com online news,Mumbai, January 27, 2026: Alembic Pharmaceuticals Limited has achieved a significant regulatory milestone with the final approval from the U.S. Food & Drug

Varahi media.com online news,Mumbai, January 27, 2026: Alembic Pharmaceuticals Limited has achieved a significant regulatory milestone with the final approval from the U.S. Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Difluprednate Ophthalmic Emulsion, 0.05%.

The newly approved product is the therapeutic equivalent of the reference listed drug (RLD), Durezol Ophthalmic Emulsion, originally by Sandoz Inc.

Read this also..Vasantha Panchami Celebrated Grandly at Pallavi International School, Nanajipur..

Medical Significance and Usage
Difluprednate Ophthalmic Emulsion is a potent corticosteroid primarily prescribed for:

Post-Surgery Recovery: Treating pain and inflammation following ocular (eye) surgeries.

Anterior Uveitis: Managing endogenous anterior uveitis, a serious inflammatory condition affecting the front of the eye.

Strengthening the U.S. Portfolio
With this latest authorization, Alembic Pharmaceuticals continues to expand its footprint in the competitive U.S. generic market. The company’s regulatory track record now includes a cumulative total of 233 ANDA approvals from the USFDA, comprising:

213 Final Approvals

20 Tentative Approvals

This approval underscores Alembic’s commitment to delivering high-quality ophthalmic solutions and its capability in navigating complex pharmaceutical manufacturing standards.